An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mawson Infrastructure Group Inc. Schedules First Quarter Results Webcast for 5PM ET on May 16, 2022
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
SYDNEY & NEW YORK--(BUSINESS WIRE)--
Mawson Infrastructure Group Inc. (NASDAQ:MIGI) (“Mawson”), a digital infrastructure provider, today announced that the company has scheduled a webcast for May 16, 2022 at 5:00 p.m. Eastern Time, to discuss results for the first quarter of 2022.
A new Investor Presentation will be available on the website at www.mawsoninc.com prior to the call.
Conference Call Information:
Date: Monday, May 16, 2022 Time: 5:00 p.m. Eastern Time Dial in Number for U.S. Callers: 1-877-407-4018
Dial in Number for International Callers: 1-201-689-8471
Please Reference Conference ID: 13729849
To join the live conference call, please dial in to the above referenced telephone numbers five to ten minutes prior to the scheduled conference call time.
A replay will be available starting on May 16, 2022 at approximately 8:00 p.m. ET through May 30, 2022 at 11:59 P.M. ET. To access the replay, please dial 1-844-512-2921 in the U.S. and 1-412-317-6671 for international callers. The conference ID# is 13729849.
About Mawson Infrastructure
Mawson Infrastructure Group (NASDAQ: MIGI) is a digital infrastructure provider, with multiple operations throughout the USA and Australia. Mawson’s vertically integrated model is based on a long-term strategy to promote the global transition to the new digital economy. Mawson matches sustainable energy infrastructure with next-generation Mobile Data Center (MDC) solutions, enabling low-cost Bitcoin production and on-demand deployment of infrastructure assets. With a strong focus on shareholder returns and an aligned board and management, Mawson Infrastructure Group is emerging as a global leader in ESG focused Bitcoin mining and digital infrastructure.
Mawson cautions that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Mawson’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the possibility that Mawson’s need and ability to raise additional capital, the development and acceptance of digital asset networks and digital assets and their protocols and software, the reduction in incentives to mine digital assets over time, the costs associated with digital asset mining, the volatility in the value and prices of cryptocurrencies and further or new regulation of digital assets. More detailed information about the risks and uncertainties affecting Mawson is contained under the heading “Risk Factors” included in Mawson’s Annual Report on Form 10-K filed with the SEC on March 21, 2022 and Mawson’s Quarterly Report on Form 10-Q filed with the SEC on November 15, 2021, and in other filings Mawson has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Mawson undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
wize pharma, inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including des. wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as lo2a, a drug developed for the treatment of des, and other ophthalmological illnesses, including cch and sjögren's syndrome (sjögren's). lo2a is currently registered and marketed by its inventor in germany and switzerland for the treatment of des, in hungary for the treatment of des, cch and sjögren's and in the netherlands for the treatment of des and sjögren's. wize's strategy involves engaging local or multinational distributors to handle the distribution of lo2a. wize has finished a phase ii trial of lo2a for patients with cch and is currently conducting a phase iv study for lo2a for des in patients with sjögren's.
